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Stroke is the third leading cause of death in the United States and the first leading cause of disability in the adult population. However, there are few effective therapies to promote postacute recovery despite the fact that numerous compounds were tested clinically.
Statins are widely used to prevent ischemic stroke and have been found to possess neurorestorative properties 1 via pleiotropic mechanisms. 2 In rodents, statins induce angiogenesis and neurogenesis after stroke and improve functional recovery. 3, 4 The effect of statins on angiogenesis and neurogenesis has been shown in different disease models. Pitavastatin increased angiogenesis in a hindlimb ischemia model via Notch1. 5 Statins have also been shown to improve neurogenesis after traumatic brain injury. 6 The mechanisms of action of statins involve many factors, including upregulating endothelial nitric oxide (NO) synthase, 3, 7 increasing nitric oxide bioavailability, 8 increasing cerebral blood flow, 7 improving endothelial dysfunction, 9 and regulating progenitor cells. 10 Although statins are promising for promoting stroke recovery, clinical trials of atorvastatin 11 and simvastatin 12 in the treatment of postacute ischemic stroke failed to show improvement in functional status.
We hypothesized that adding another agent with a synergistic effect with statins would potentiate the effect in promoting recovery. Phosphodiesterase-5 inhibitors (e.g., sildenafil, vardenafil, and tadalafil) are another class of neurorestorative drugs that modulate NO signaling. They inhibit cyclic guanosine monophosphate (cGMP) and cGMP hydrolysis, thereby elevating cGMP levels. Sildenafil was found to increase cGMP and promote neurogenesis and motor recovery in stroke rats. 13, 14 However, a study of facial nerve crush injury in rodents failed to show neuroprotection by sildenafil. 15 The conflicting data suggest that sildenafil alone might not be a potent neuroprotective agent. On the other hand, sildenafil has been shown to produce a synergistic effect with statins in the cardiovascular system via the NO pathway. 16, 17 Furthermore, pretreatment with combined simvastatin and dipyridamole, a phosphodiesterase 5 inhibitor, improved cerebral blood flow after stroke via the NO pathway. 18 However, it is not clear if a combination of statin with a phosphodiesterase-5 inhibitor promotes long-term recovery after cerebral ischemia.
In this study, we tested the hypothesis that a combination of atorvastatin and sildenafil generates an additive effect in promoting recovery after is-chemic stroke in mice. We selected sildenafil instead of dipyridamole because sildenafil has been shown to have a neurorestorative effect, whereas there is no evidence of dipyridamole promoting neuroplasticity.
METHOD

Study Design
C57BL/6 adult mice were subjected to 60 mins of transient middle cerebral artery occlusion. The adhesive removal test was performed on postoperative day 1. To get a balanced baseline in each group, mice were randomized based on the adhesive removal test and stratified into four treatment groups: placebo (water), atorvastatin (0.3 mg/kg), sildenafil (0.3 mg/kg), or a combination of atorvastatin (0.3 mg/kg) and sildenafil (0.3 mg/kg). Drugs were administered by oral gavage starting 24 hrs after ischemia and then daily for 6 days. The treatment was started 24 hrs after ischemia to demonstrate the neurorestorative effect of the drugs. 14 Behavioral studies (neurologic score and adhesive removal test) were performed at baseline (presurgery), on postoperative day 1, and on postoperative day 7. The cylinder test was performed at baseline and on postoperative day 7 because on postoperative day 1, animals were too weak to perform the test. To determine the histologic tissue outcome, infarct volume and cerebral capillary length were measured.
Ischemia Model
Adult male mice (wild-type C57 black/6; age, 2Y3 mos; weight, 22Y25 g) were purchased from Charles River Laboratories (Wilmington, MA). All experiments were performed following an institutionally approved protocol in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Mice were housed under diurnal lighting conditions and had free access to food and water. To generate focal cerebral ischemia, a transient monofilament occlusion method was used. Briefly, 2% isoflurane was used to induce anesthesia followed by 1% isoflurane with 70% N 2 O/30% O 2 to maintain anesthesia. Rectal temperature was monitored and maintained at 37-C T 0.5-C using a thermostatic heating pad (Frederick Haer and Co., Brunswick, ME). Blood flow at the middle cerebral artery territory was monitored using a flexible fiber optic probe (PF2B; Perimed, Stockholm, Sweden). To generate MCA occlusion, a commercially available nylon filament (Doccol Corp) was inserted into the external carotid artery and advanced to the middle cerebral artery. The MCA occlusion was confirmed by a greater than 80% reduction in blood flow. The monofilament was removed after 60 mins of occlusion.
Behavioral Study
Neurologic Score
General neurologic deficit was assessed using a four-point (0Y3) neurologic score test: 0 = no deficit, 1 = failure to fully extend the forepaw, 2 = circling to one side, 3 = no spontaneous walking with a depressed level of consciousness. 7
Adhesive Removal Test
The adhesive removal test measures sensorimotor function. A small piece of adhesive tape (3 mm Â 4 mm) was placed on each forepaw, and the amount of time (seconds) needed to contact and remove the tape from each forepaw was recorded. Observation stopped at 4 mins. Three runs were performed, and the best score was used in the analysis. Mice were trained three times before the surgery to ensure that they were able to remove the tape in fewer than 50 secs. 19 
Cylinder Test
The asymmetry of forelimb movements was measured using the cylinder test. 20 Mice were placed in a Plexiglas cylinder. The number of contacts of left, right, or both forepaws with the cylinder wall was recorded. The recording was stopped after the total number of contacts reached 20 or after 15 mins. The data point was excluded if animals had fewer than 10 contacts in 15 mins. The test was performed at baseline before surgery and on postoperative day 7. The lateralization index was calculated as (number of right side placement j number of left side placement)/total placement.
Infarct Size Measurement
To measure the infarct size, fresh-frozen brain sections were stained using hematoxylin-eosin. The infarct volume was measured with an imaging system (MCID; Interfocus Imaging, Cambridge, UK). Indirect volumes in percentage of the contralateral side were calculated. 3 Pearson W 2 = 0.168, P = 0.983.
FIGURE 1
Cumulative daily mortality rate. Cumulative daily mortality rate = cumulative daily mortality/total mice subjected to middle cerebral artery occlusion in each group. Body weight on POD 1 and 7 is expressed as percentage of presurgery weight. Two-way ANOVA showed no significant difference for either the time factor (F 1,17 = 15, P 9 0.05) or the treatment factor (F 3,17 = 0.82, P 9 0.05). POD, postoperative day; ANOVA, analysis of variance.
CD31 Immunohistochemistry
Cerebral vascular endothelium cells were labeled with an antibody against CD31 (n = 7Y8 mice/ group) as described. 21 Brains were fresh-frozen and sectioned with a cryostat. Sections were stained with mouse anti-CD31 monoclonal antibody overnight (1:200 dilution; Abcam, Cambridge, MA). A secondary antibody that was used was antimouse goat Cy3 conjugates (1:500 dilution; Jackson Im-munoResearch Laboratories, West Grove, PA). To measure the length of CD31-positive blood vessels, four sections from each brain at bregma 0.9, 0.6, 0.3, and j0.1 were obtained. Three areas in each brain section were measured: striatum in contralateral, infarct, and peri-infarct. Four fields were selected at approximately the same location in each area, and the total length of CD31-positive vessels (mm) within the field was measured using image analysis software (MCID Elite). The measurement was conducted by an investigator who was blinded to the treatment.
Statistical Analysis
Mortality rate was analyzed using W 2 analysis. Data are reported as mean T SD, except for neurologic scores, which are reported as median (range). On the basis of our hypothesis that combination treatment is better than individual-drug treatment group in outcome variables including adhesive removal test and cylinder test, we used linear regression model 22 to compare the combination treatment group with the individual-drug treatment group and placebo on postoperative day 7 for adhesive removal test and cylinder test. For adhesive removal test, we used linear regression with censoring (Tobit regression model) because the outcome variables are censored (maximum score is 240 secs). Two-way analysis of variance (ANOVA) was performed to analyze the difference in body weight and neurologic scores on postoperation days 1 and 7. ANOVA was performed to analyze the difference in infarct volume and cerebral capillary length among all four groups because the null hypothesis is that there is no difference among the groups in the above outcomes. P values G0.05 were considered significant. There was no correction for multiple testing.
RESULTS
Mortality
A total of 67 mice were included in the study. Mortality rate ranged from 35% to 41% in each group, and there was no significant difference among the groups (P = 0.983, Table 1 and Fig. 1 ). Mice that died within 24 hrs after middle cerebral artery occlusion were excluded from the study. Mice that were included but died before the seventh day were excluded from behavioral and tissue outcome studies.
Body Weight
Body weight was measured after the middle cerebral artery occlusion. The percentage of body weight to presurgery weight is reported in Table 2 . All groups showed weight reduction during the course of 7 days after middle cerebral artery occlusion. Two-way ANOVA showed no significant difference for either the time factor (F 1,17 = 15, P 9 0.05) or the treatment factor (F 3,17 = 0.082, P 9 0.05). 
Body weight on POD 1 and 7 is expressed as percentage of presurgery weight. Two-way ANOVA showed no significant difference for either the time factor (F 1,17 = 15, P 9 0.05) or the treatment factor (F 3,17 = 0.82, P 9 0.05). POD, postoperative day; ANOVA, analysis of variance. A small piece of adhesive tape was placed on the hairless part of the forepaw bilaterally. The time in seconds that the animals took to remove the adhesive tape on the hemiplegic forepaw is reported. The maximum time recorded was 240 secs. Linear regression with censoring was used to compare combination with placebo, sildenafil, and atorvastatin groups on postoperative day (POD) 7. Data are presented as mean T SD.
Functional Outcome
To measure functional outcome, neurologic score, adhesive removal test, and cylinder test were performed. For neurologic score, animals displayed improved function from postoperative day 1 to postoperative day 7 regardless of treatment (time factor, F 1,38 = 240, P G 0.01, two-way ANOVA). There were no significant differences among the treatment groups (treatment factor, F 3,38 = 0.49, P 9 0.05, Table 3 ). For adhesive removal test, Tobit regression revealed that on postoperative day 7, the combination group was significantly better in the removal time (seconds) of adhesive tape on the lesioned limb (50 T 54) as compared with the control group (147 T 109) (P G 0.05) and to atorvastatin (144 T 102) (P G 0.05) but did not show statistically significant improvement compared with sildenafil (107 T 115) (P = 0.148) ( Table 4 ). On the other hand, neither atorvastatin nor sildenafil alone improved the adhesive removal test as compared with control (P 9 0.05). There was no significant difference in the contact time in each limb or the removal time in the normal limb (as seen in appendix Tables IYIII). For the cylinder test, the lateralization index was 0.3 T 0.35 in the vehicle group, j0.057 T 0.36 after atorvastatin treatment, j0.046 T 0.36 after sildenafil treatment, and 0.07 T 0.24 for combination treatment. There was no significant dif-ference for combination compared with placebo or individual treatment using linear regression analysis ( Table 5 ). For the sildenafil treatment group, one data point was excluded because the animal touched the cylinder walls only five times in 15 mins.
Infarct Volume
Indirect infarct volume was measured as described. 3 As shown in Table 6 , there was no significant difference among the groups as analyzed using ANOVA.
Capillary Length
As shown in Table 7 and Figure 2AYC , there was no difference in total capillary lengths among the four groups as analyzed using ANOVA.
DISCUSSION
Our data suggest that a combination of atorvastatin and sildenafil at subclinical dose is significantly better than atorvastatin alone on a single variable (adhesive removal test) out of multiple variables tested. The adhesive removal study tests sensory and fine motor function. The latter involves both forepaws and mouth. The removal time from the hemiplegic limb was significantly improved in the combination treatment group, whereas there was no significant difference in contact time. The data suggest that the improvement might be a result of improvement in fine motor function but not sensory function. Gross motor function as measured by neurologic score and cylinder test did not show any difference among the groups.
However, combination treatment was not better than sildenafil alone. It is possible that the effect of combination treatment was mostly caused by the effect of sildenafil. However, at this subclinical dose, neither atorvastatin nor sildenafil alone improved sensorimotor function as compared with control, which suggests that there is an additive effect of the two drugs. The enhanced efficacy On POD 7, brain slices were stained with hematoxylin and eosin, and the percentage of indirect infarct volume of contralateral was calculated. ANOVA was used for statistical analysis. Data are presented as mean T SD. POD, postoperative day; ANOVA, analysis of variance.
of the combination of atorvastatin and sildenafil has been demonstrated in other systems, including myocardial infarction, 16, 17 erectile dysfunction, 23 and hypertension. 24 The data suggest that combination treatment might be potentially a more potent therapy than individual-drug treatment.
Because mice have good spontaneous recovery after stroke and motor function tests may show a ceiling effect, we used subclinical doses of atorvastatin and sildenafil to detect the difference between combination treatment and individual-drug treatment.
The mechanism of this combination in promoting stroke recovery is not clear. It is possible that a combination of atorvastatin and sildenafil induces a synergistic effect by activating the NO/ cGMP pathway. Atorvastatin induces NO production, which leads to the generation of cGMP. Sildenafil inhibits cGMP hydrolysis, which leads to the accumulation of cGMP. 25 NO causes vessel dilation, which leads to improved cerebral perfusion, 7 and induces angiogenesis 26 as well as neurogenesis. 27 In addition, NO also plays a role in reducing brain vascular inflammation and leakage. 28 All of the above functions have been shown to contribute to brain plasticity and functional recovery after stroke. Improved cerebral perfusion, 7 blood-brain barrier repair, 29 and reduced inflammation 30 have been shown to play important roles in early phase stroke recovery. Angiogenesis and neurogenesis are likely to play a role in late phase recovery. Our data show improved motor recovery at 7 days after ischemia without affecting capillary length. This may indicate that early events such as cerebral perfusion, blood-brain barrier repair, and inflammation reduction might play major roles in this recovery. Furthermore, as expected, the treatment did not affect infarct volume, probably because the treatment was started 24 hrs after ischemia.
In conclusion, the data suggest that combined atorvastatin and sildenafil might be a better treatment regimen than single-drug treatment. However, the effects observed are not robust. Further studies are needed to optimize the treatment conditions, such as dosing, timing, and duration of the combination treatment, and to elucidate the mechanism of action.
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ANOVA, analysis of variance. A small piece of adhesive tape was placed on the hairless part of each forepaw. The time in seconds that the animals took to contact and remove the adhesive tape on the forepaw was recorded. The maximum time recorded was 240 secs. Linear regression with censoring (Tobit regression) showed no significant difference as combination treatment compared with placebo, sildenafil, or atorvastatin groups on postoperative day (POD) 7. Data are presented as mean T SD. Tobit regression showed no significant difference as combination treatment compared with placebo, sildenafil, or atorvastatin groups on postoperative day (POD) 7. Data are presented as mean T SD.
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APPENDIX TABLE II Left-side tape contact time in the adhesive removal test
